-
Je něco špatně v tomto záznamu ?
Treatment of central serous chorioretinopathy with beta-blocker metipranolol
O. Chrapek, B. Jirkova, V. Kandrnal, J. Rehak, M. Sin
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, randomizované kontrolované studie
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
- MeSH
- aplikace orální MeSH
- beta blokátory aplikace a dávkování MeSH
- centrální serózní chorioretinopatie diagnóza farmakoterapie patofyziologie MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- lidé MeSH
- macula lutea účinky léků patologie MeSH
- metipranolol aplikace a dávkování MeSH
- následné studie MeSH
- optická koherentní tomografie MeSH
- prospektivní studie MeSH
- výsledek terapie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- zraková ostrost MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
AIM: The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC). METHODS: A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium. RESULTS: There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341). CONCLUSIONS: In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17006047
- 003
- CZ-PrNML
- 005
- 20170331111703.0
- 007
- ta
- 008
- 170210s2015 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2013.015 $2 doi
- 035 __
- $a (PubMed)23549516
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Chrapek, Oldřich, $u Department of Ophthalmology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic $d 1969- $7 xx0037582
- 245 10
- $a Treatment of central serous chorioretinopathy with beta-blocker metipranolol / $c O. Chrapek, B. Jirkova, V. Kandrnal, J. Rehak, M. Sin
- 520 9_
- $a AIM: The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC). METHODS: A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium. RESULTS: There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341). CONCLUSIONS: In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a beta blokátory $x aplikace a dávkování $7 D000319
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a centrální serózní chorioretinopatie $x diagnóza $x farmakoterapie $x patofyziologie $7 D056833
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a macula lutea $x účinky léků $x patologie $7 D008266
- 650 _2
- $a metipranolol $x aplikace a dávkování $7 D014290
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a optická koherentní tomografie $7 D041623
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a zraková ostrost $7 D014792
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Chrapková, Barbora $7 xx0238672 $u Department of Ophthalmology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Kandrnal, Vít $7 _AN055561 $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno
- 700 1_
- $a Řehák, Jiří, $d 1958- $7 nlk19990074207 $u Department of Ophthalmology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 700 1_
- $a Šín, Martin $7 xx0095569 $u Department of Ophthalmology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 159, č. 1 (2015), s. 120-123
- 856 41
- $u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20170210 $b ABA008
- 991 __
- $a 20170331111948 $b ABA008
- 999 __
- $a ok $b bmc $g 1192577 $s 966694
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 159 $c 1 $d 120-123 $e 20130321 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20170210
